Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system - 13/12/18
Doi : 10.1016/j.jaad.2018.04.017
Lena A. von Schuckmann, MBBS, MPH a, b, ⁎ 
, Maria Celia B. Hughes, MMedSci a, Rebecca Lee, MBChB c, Paul Lorigan, MB, FRCP d, Kiarash Khosrotehrani, MD, PhD e, B. Mark Smithers, MBBS f, Adele C. Green, MBBS, PhD a, c
, Maria Celia B. Hughes, MMedSci a, Rebecca Lee, MBChB c, Paul Lorigan, MB, FRCP d, Kiarash Khosrotehrani, MD, PhD e, B. Mark Smithers, MBBS f, Adele C. Green, MBBS, PhD a, c a Population Health Department, Queensland Institute of Medical Research Berghofer Medical Research Institute, Herston, Australia
b School of Public Health, The University of Queensland, Herston, Australia
c Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
d University of Manchester and Christie National Health Service Foundation Trust, Manchester, United Kingdom
e Experimental Dermatology Group, The University of Queensland Diamantina Institute, Woolloongabba, Australia
f Queensland Melanoma Project, Princess Alexandra Hospital, The University of Queensland, Woolloongabba, Australia
∗Correspondence to: Lena A. von Schuckmann, MBBS, MPH, QIMR Berghofer Institute of Medical Research, 300 Herston Road, 4006 Herston, AustraliaQIMR Berghofer Institute of Medical Research300 Herston Road4006 HerstonAustralia
| Funding sources: Supported by National Health and Medical Research Council (NHMRC) program grants 1073898 and 552429. Dr von Schuckmann is funded by NHMRC postgraduate scholarship 1133317. Dr Khosrotehrani was funded by a NHMRC Career Development Fellowship. |
|
| Disclosure: Prof Lorigan has used a grant provided by Bristol-Myers Squibb and received honoraria from Pierre Fabre, Nera Care, Amgen, MSD, Novartis, and Bristol-Myers Squibb for participating in research projects outside this work. Dr von Schuckmann, Ms Hughes, Dr Lee, Prof Lorigan, A/Prof Kiarash Khosrotehrani, Prof Smithers, and Prof Green have no conflicts of interest to disclose. |
|
| The funding body played no role in the study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the article for publication. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 80 - N° 1
P. 272-274 - janvier 2019 Retour au numéro
Article précédent
- Review of environmental effects of oxybenzone and other sunscreen active ingredients
- Samantha L. Schneider, Henry W. Lim
- Pharmacy costs of specialty medications for plaque psoriasis in the United States
- Eric J. Yang, Kristen M. Beck, Sahil Sekhon, Tina Bhutani
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?